Asia Tumbles, Tesla...
Health Care: Drugs
EntreMed Inc. (ENMD: NASDAQ)
$1.78 -0.02 | -1.11%
05/23/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -14.55M | -4.56M | -8.10M | -8.22M |
| Operating Gains/Losses | 0.00 | -9.50K | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 1.26M | 817.70K | 536.46K | 630.58K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 138.20K | -897.68K | -617.60K | -1.53M |
| (Decrease) Increase In Other Current Liabilities | 0.00 | -344.58K | -149.84K | -1.86M |
| (Increase) Decrease In Other Working Capital | -99.54K | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 11.02M | 609.72K | 3.35M | 524.17K |
| Net Cash From Continuing Operations | -2.21M | -4.27M | -4.96M | -10.21M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -2.21M | -4.27M | -4.96M | -10.21M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 26.81K | 0.00 | 15.50M |
| Purchases of Property, Plant & Equipment | -48.39K | -6.00K | -3.60K | -2.89K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | -7.99M |
| Other Cash from Investing Activities | 0.00 | 56.50K | 2.00K | -4.44K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -48.39K | 77.31K | -1.60K | 7.50M |
| Issuance of Debt | 10.00M | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 2.00K | 1.31M | 0.00 | 0.00 |
| Repayment of Long-Term Debt | 0.00 | -757.47K | -8.55M | -7.71M |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -772.81K | -164.96K | 12.09M | -10.32K |
| Net Cash From Financing Activities | 9.23M | 389.63K | 3.54M | -7.72M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 6.97M | -3.81M | -1.43M | -10.43M |
Portfolios with ENMD
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- Contributor6 Drug Stocks Unworthy of B...
- UserBeaver
- Contributor10 Stocks Under $5 Outperfo...
- ContributorStocks Under $5 at Risk of ...
- UserDorkingLad Portfolio 1
- Usersmallbiz
- Usersteves #1
- UserThe Investment Psychologist...
- Userdrweik Portfolio 1
Latest ENMD Headlines from TheStreet
- 7 Stocks Under $10 Making Big Moves Higher 07.05.12 | 02:07 pm
- 6 Drug Stocks Unworthy of Biotech Bull Market 02.07.12 | 12:02 pm
- 5 Stocks Under $10 Poised for Big Upside 02.03.12 | 02:02 pm
- 10 Stocks Under $5 Outperforming in 2012 01.31.12 | 05:01 am
- Stocks Under $5 at Risk of Bankruptcy 06.08.11 | 06:06 am
- Biotech Sector Weekly Rewind 11.20.10 | 08:11 am
- Stock Offerings: Two Harbors 04.19.10 | 10:04 am
- Sprint Nextel, Palm: Early Volume Plays 04.19.10 | 07:04 am
- ThermoGenesis, Power-One: Early Volume Plays 02.05.10 | 07:02 am
- Netlist, EntreMed: Midday Volume Plays 12.14.09 | 02:12 pm
Press Releases for ENMD
- EntreMed Announces Changes To Board Of Directors And CEO Appointment - PR Newswire 04.05.13 | 07:04 am
- EntreMed To Raise $10.7 Million In Registered Direct Offering - PR Newswire 03.01.13 | 08:03 am
- EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma - PR Newswire 01.23.13 | 07:01 am
- EntreMed Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA To Advance Global Development Strategy - PR Newswire 01.07.13 | 07:01 am
- EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer - PR Newswire 01.04.13 | 07:01 am
- PNAS Publishes Preclinical Results Of EntreMed's 2ME2 For Multiple Sclerosis - PR Newswire 12.04.12 | 01:12 pm
- EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer - PR Newswire 11.26.12 | 07:11 am
- Dana-Farber Cancer Institute's Ursula A. Matulonis, MD Article On EntreMed's ENMD-2076 Published In The European Journal Of Cancer - PR Newswire 09.06.12 | 07:09 am
- EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer - PR Newswire 07.25.12 | 07:07 am
- EntreMed Appoints Interim CEO - PR Newswire 04.03.12 | 07:04 am
Partner Headlines for ENMD
- Morning Market Movers - Benzinga 11.26.12 | 09:11 am
- Alexandria Leases to NIH - Analyst Blog - NASDAQ 09.07.12 | 08:09 pm
- China Biotech In Review: GSK Explores All Paths To Increase China Presence - Seeking Alpha 03.11.12 | 07:03 am
- China Biotech Week in Review: Shanghai Pharma Plans $1.2 Billion IPO - Seeking Alpha 09.12.10 | 09:09 am
- Big Pharma Looks to Biotech for Innovation - Seeking Alpha 09.12.10 | 08:09 am
- EntreMed Widens Loss in 2Q, Clinical Trials for Ovarian Cancer Progress - Fox Business 08.16.10 | 12:08 pm
